Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar

Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.